16:15 Keynote Chairperson’s Remarks

Denise L. FaustmanDenise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General Hospital

16:20 Learning from What Works: Dissection of Successful Cancer Clearance by the Immune System

Andrew SewellAndrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Division of Infection and Immunity, Cardiff University School of Medicine

What is the key to success? How do some rare patients spontaneously clear extreme cancer? What is being recognised by T cells during successful tumour-infiltrating lymphocyte or T cell checkpoint therapy? We have developed two new methodologies that allow rapid determination of the ligand recognised by any ‘orphan’ T cell clone. These techniques have enabled us to address these questions and discover novel cancer-associated epitopes expressed by most cancers.

17:05 mAbs vs. Bugs: Antibody Therapies for Infectious Disease

Stephen-MartinSteve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKline

This year’s coronavirus pandemic has provided a stark reminder of the threa to global health posed by infectious disease and the need for new treatments. Renewed attention has been brought to the potential of antibodies as anti-infective therapeutics, which historically has been a challenging area for drug discovery. Synergies between modern vaccine development approaches and antibody discovery technologies offer new opportunities in the fight against our microbial foes.


Synergistic Effect of Hydrodynamic Flow and Interfaces on Antibody Aggregation
Paolo Arosio, PhD, Assistant Professor, Chemistry & Applied Biosciences, ETH Zurich

TriTACs – A Next Generation of T Cell-Engaging Antibody Constructs for Solid Tumor Therapy
Patrick Baeuerle, PhD, Managing Director, MPM Capital LLC

Development of Site-Specifically Conjugated, Anthracycline-Based Immune-Stimulatory ADCs (iADCs)
Roger Beerli, PhD, CSO, NBE-Therapeutics Ltd.

Novel Cytokine-Grafting Technique Generates Potent Interleukin-2 Immunotherapy with Efficacy in Multiple Cancer Models
Onur Boyman, Professor & Chair, Immunology, University Hospital Zurich

ATMP Potency: Metrological Considerations
Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd.

Rapid and Nimble Expression and Production Tools: Lessons Learned over the Past Few Months
Nicola A. Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium

Antibody Discovery Is More than Just Binders
Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline

Towards ML-Enabled Antibody Drug Discovery at Bayer: Vision and Step-Wise Approach
Philipp Ellinger, Dr rer nat, Lab Head, Analytical Biochemistry, Biologics Research, Cell, Gene and Protein Sciences, Bayer AG

Between Checkpoints and Targeting: Next-Generation Immune Therapies for Solid Cancers
Bent Jakobsen, PhD, FMedSci, CEO/CSO, OXANT Technology Ventures

Highly Targeted Anticalin® Therapies
Hitto Kaufmann, PhD, CSO & Senior Vice President, Pieris Pharmaceuticals GmbH

Emerging Cell-Line Engineering Tools: What Shall We Watch for?
Lorenz Mayr, PhD, Visiting Scientist and Guest Professor, ETH Zurich; Entrepreneur in Residence, Syncona Ltd.

Immunocytokines with “Activity on Demand”
Dario Neri, PhD, Full Professor, Chemistry & Applied Biosciences, ETH Zurich

Next-Generation T Cell Engagers
Paul Parren, PhD, Executive Vice President & Head, Lava Therapeutics

Why We Develop Autoimmune Diseases: Hyperstimulation of the Immune System
Yehuda Shoenfeld, MD, FRCP, MaACR, Past Incumbent of the Laura Schwarz-Kipp Chair, Research of Autoimmune Diseases, Tel-Aviv University

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Éric Vivier, PhD, CSO, Innate Pharma

Get the Optimal Glycan: Tailor-Made and Controlled Glycosylation of Therapeutic Proteins
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark

Evaluating a New Technology in the Context of Historical Successes and Failures: A Case Study on Self- Cleaving Tags
David W. Wood, PhD, Professor, Chemical & Biomolecular Engineering, The Ohio State University